{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T07:09:09Z","timestamp":1793776149810,"version":"4.6.1"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T00:00:00Z","timestamp":1691971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Generalized bullous fixed drug eruption (GBFDE) is the most severe form of fixed drug eruption and can be misdiagnosed as epidermal necrolysis (EN). We report the case of a 42-year-old male patient presenting with more than 50% skin detachment without defined areas of exanthema or erythema and a history of one prior event of EN caused by acetaminophen (paracetamol), allopurinol, or amoxicillin 1.5 years ago. The initial diagnosis was GBFDE or EN. The histology of a skin biopsy was unable to distinguish between the two diseases. The course of the disease, the later clinical presentation, and the medical and medication history, however, were in favor of a diagnosis of GBFDE with two potentially culprit drugs: metamizole and ibuprofen. Moxifloxacin, enoxaparin sodium, hydromorphone, and insulin human were administered concomitantly, which makes them suspicious as well. Unfortunately, the patient received an additional dose of metamizole, one of the possible causative drugs, and he developed another bullous reaction within 1 month. This led to the diagnosis of GBFDE due to metamizole. This report highlights the challenges of distinguishing two rare diseases and elucidates the importance of distinct clinical presentation and detailed medication history.<\/jats:p>","DOI":"10.3389\/fmed.2023.1125754","type":"journal-article","created":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T23:28:25Z","timestamp":1692055705000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Case report: Generalized bullous fixed drug eruption mimicking epidermal necrolysis"],"prefix":"10.3389","volume":"10","author":[{"given":"Maren","family":"Paulmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Reinkemeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Lehnhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Mockenhaupt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"925","DOI":"10.3390\/medicina57090925","article-title":"A review of fixed drug eruption with a special focus on generalized bullous fixed drug eruption","volume":"57","author":"Anderson","year":"2021","journal-title":"Medicina"},{"key":"B2","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1111\/bjd.12133","article-title":"Prognosis of generalized bullous fixed drug eruption: comparison with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"168","author":"Lipowicz","year":"2013","journal-title":"Br J Dermatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/j.1365-2133.1985.tb15266.x","article-title":"Fixed eruptions: causative drugs and challenge tests","volume":"112","author":"Kauppinen","year":"1985","journal-title":"Br J Dermatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00105-016-3850-y","article-title":"Unintended rechallenge: generalized bullous fixed drug eruption in two elderly women","volume":"68","author":"Paulmann","year":"2017","journal-title":"Hautarzt."},{"key":"B5","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/ACI.0b013e32832cda4c","article-title":"Fixed drug eruption: pathogenesis and diagnostic tests","volume":"9","author":"Shiohara","year":"2009","journal-title":"Curr Opin Allergy Clin Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s40629-019-00111-8","article-title":"Severe skin reactions: clinical picture, epidemiology, etiology, pathogenesis, and treatment","volume":"28","author":"Paulmann","year":"2019","journal-title":"Allergo J Int."},{"key":"B7","first-page":"215","article-title":"Fixed drug eruptions: a case report and review of the literature","volume":"84","author":"Gendernalik","year":"2009","journal-title":"Cutis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/j.1365-4362.1988.tb04923.x","article-title":"Widespread bullous fixed drug eruption mimicking toxic epidermal necrolysis","volume":"27","author":"Baird","year":"1988","journal-title":"Int J Dermatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"376","DOI":"10.2340\/00015555-2840","article-title":"Generalized bullous fixed drug eruption following metamizole (re-)exposure: a medical error-analytic case study","volume":"98","author":"Elsner","year":"2018","journal-title":"Acta Derm Venereol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1503709","DOI":"10.1155\/2017\/1503709","article-title":"Treatments for severe cutaneous adverse reactions","volume":"2017","author":"Cho","year":"2017","journal-title":"J Immunol Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1111\/bjd.13989","article-title":"Epidermal necrolysis: 60 years of errors and advances","volume":"173","author":"Heng","year":"2015","journal-title":"Br J Dermatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1111\/j.1365-2133.1990.tb06275.x","article-title":"Requiem for toxic epidermal necrolysis","volume":"122","author":"Lyell","year":"1990","journal-title":"Br J Dermatol."},{"key":"B13","article-title":"Epidermal necrolysis (stevens-johnson syndrome and toxic epidermal necrolysis)","author":"Mockenhaupt","year":"2019","journal-title":"Fitzpatrick's Dermatology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S0190-9622(85)70207-1","article-title":"Acute disseminated epidermal necrosis types 1, 2, and 3: study of sixty cases","volume":"13","author":"Ruiz-Maldonado","year":"1985","journal-title":"J Am Acad Dermatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1001\/archderm.129.1.92","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch Dermatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.5070\/D3237035734","article-title":"Generalized bullous fixed drug eruption imitating toxic epidermal necrolysis: a case report and literature review","author":"Mitre","year":"2017","journal-title":"Dermatol Online J"},{"key":"B17","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1001\/archderm.120.4.520","article-title":"Fixed drug eruption. A brief review","volume":"120","author":"Korkij","year":"1984","journal-title":"Arch Dermatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.dsi.2012.02.002","article-title":"Fixed-drug eruption: a retrospective study in a single referral center in northern Taiwan","volume":"30","author":"Lee","year":"2012","journal-title":"Dermatol Sin."},{"key":"B19","first-page":"39","article-title":"Generalized bullous fixed drug eruption: analysis of 62 cases","volume":"42","author":"Mockenhaupt","year":"2010","journal-title":"Eur Ann Allergy Clin Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jaad.2013.11.015","article-title":"Generalized bullous fixed drug eruption is distinct from Stevens-Johnson syndrome\/toxic epidermal necrolysis by immunohistopathological features","volume":"70","author":"Cho","year":"2014","journal-title":"J Am Acad Dermatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1365-2133.1956.tb12766.x","article-title":"Toxic epidermal necrolysis: an eruption resembling scalding of the skin","volume":"68","author":"Lyell","year":"1956","journal-title":"Br J Dermatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.jemermed.2014.09.049","article-title":"Bullous fixed drug eruption masquerading as recurrent Stevens Johnson syndrome","volume":"48","author":"Dharamsi","year":"2015","journal-title":"J Emerg Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1684\/ejd.2016.2884","article-title":"Illustration of diagnostic and prognostic difficulties during the early stages of generalized bullous fixed drug eruptions","volume":"27","author":"Bataille","year":"2017","journal-title":"Eur J Dermatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.5826\/dpc.0101a09","article-title":"Histopathology of drug eruptions - general criteria, common patterns, and differential diagnosis","volume":"1","author":"Weyers","year":"2011","journal-title":"Dermatol Pract Concept."},{"key":"B25","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1684\/ejd.2021.4051","article-title":"Clinical and histological features of fixed drug eruption: a single-centre series of 73 cases with comparison between bullous and non-bullous forms","volume":"31","author":"Perron","year":"2021","journal-title":"Eur J Dermatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2165\/00128071-200001050-00003","article-title":"Fixed drug eruptions. Incidence, recognition, and avoidance","volume":"1","author":"Lee","year":"2000","journal-title":"Am J Clin Dermatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1111\/j.1365-4632.2006.02853.x","article-title":"Fixed drug eruption (FDE): changing scenario of incriminating drugs","volume":"45","author":"Sehgal","year":"2006","journal-title":"Int J Dermatol."},{"key":"B28","doi-asserted-by":"crossref","DOI":"10.5772\/22335","article-title":"Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy","volume-title":"Skin Biopsy.","author":"Ziemer","year":"2011"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1111\/ddg.14870","article-title":"Fixed drug eruptions - the common and novel culprits since 2000","volume":"20","author":"McClatchy","year":"2022","journal-title":"J Dtsch Dermatol Ges."},{"key":"B30","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S0190-9622(83)70060-5","article-title":"Pigmentary incontinence in fixed drug eruptions. Histologic and electron microscopic findings","volume":"8","author":"Masu","year":"1983","journal-title":"J Am Acad Dermatol."},{"key":"B31","first-page":"572","article-title":"Clinical resemblance of widespread bullous fixed drug eruption to Stevens-Johnson syndrome or toxic epidermal necrolysis: report of two cases","volume":"101","author":"Lin","year":"2002","journal-title":"J Formos Med Assoc."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.jfma.2021.09.025","article-title":"Analysis of severe cutaneous adverse reactions (SCARs) in Taiwan drug-injury relief system: 18-year results","volume":"121","author":"Huang","year":"2022","journal-title":"J Formos Med Assoc."},{"key":"B33","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/cod.13351","article-title":"Clinical features, culprit drugs, and allergology workup in 41 cases of fixed drug eruption","volume":"81","author":"Ben Fadhel","year":"2019","journal-title":"Contact Dermat."},{"key":"B34","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1684\/ejd.2010.0980","article-title":"A three-year-analysis of fixed drug eruptions in hospital settings in France","volume":"20","author":"Brahimi","year":"2010","journal-title":"Eur J Dermatol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/clpt.2009.252","article-title":"ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis","volume":"88","author":"Sassolas","year":"2010","journal-title":"Clin Pharmacol Ther."},{"key":"B36","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J Invest Dermatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1046\/j.1365-4362.1998.00451.x","article-title":"Drugs causing fixed eruptions: a study of 450 cases","volume":"37","author":"Mahboob","year":"1998","journal-title":"Int J Dermatol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s40257-020-00505-3","article-title":"Fixed drug eruptions: an update, emphasizing the potentially lethal generalized bullous fixed drug eruption","volume":"21","author":"Patel","year":"2020","journal-title":"Am J Clin Dermatol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/j.1525-1470.1995.tb00149.x","article-title":"Clinical pattern of cutaneous drug eruption among children and adolescents in north India","volume":"12","author":"Sharma","year":"1995","journal-title":"Pediatr Dermatol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1159\/000248578","article-title":"Ninety-eight fixed drug eruptions with provocation tests","volume":"177","author":"Kanwar","year":"1988","journal-title":"Dermatologica."},{"key":"B41","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/ijd.12197","article-title":"Fixed drug eruption in Bangladeshi population: confirmed by provocative test","volume":"53","author":"Rahman","year":"2014","journal-title":"Int J Dermatol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"236703","DOI":"10.1155\/2015\/236703","article-title":"Clinical features and drug characteristics of patients with generalized fixed drug eruption in the West of Iran (2005-2014)","volume":"2015","author":"Kavoussi","year":"2015","journal-title":"Dermatol Res Pract."},{"key":"B43","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/ddg.13468","article-title":"Changing trends in inducer drugs of fixed drug eruption: a 20-year cross-sectional study from Turkey","volume":"16","author":"\u00d6zkaya","year":"2018","journal-title":"J Dtsch Dermatol Ges."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1111\/jdv.12919","article-title":"An update of fixed drug eruptions in Singapore","volume":"29","author":"Heng","year":"2015","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"415","DOI":"10.4168\/aair.2014.6.5.415","article-title":"Clinical features of fixed drug eruption at a tertiary hospital in Korea","volume":"6","author":"Jung","year":"2014","journal-title":"Allergy Asthma Immunol Res."},{"key":"B46","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/j.1346-8138.1984.tb01492.x","article-title":"Drugs causing fixed eruptions","volume":"11","author":"Kanwar","year":"1984","journal-title":"J Dermatol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1097\/00007435-198407000-00009","article-title":"Fixed drug eruptions on male genitalia: clinical and etiologic study","volume":"11","author":"Pandhi","year":"1984","journal-title":"Sex Transm Dis."},{"key":"B48","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/00000441-200502000-00007","article-title":"Intravenous immunoglobulin for treatment of toxic epidermal necrolysis","volume":"329","author":"Nasser","year":"2005","journal-title":"Am J Med Sci."},{"key":"B49","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/cod.12641","article-title":"Patch testing in the investigation of non-immediate cutaneous adverse drug reactions to metamizole","volume":"76","author":"Pinho","year":"2017","journal-title":"Contact Dermatitis."},{"key":"B50","doi-asserted-by":"publisher","first-page":"832","DOI":"10.5336\/medsci.2010-18328","article-title":"Dipyrone, great killer or innocent as any drug: two case reports presenting rare and life-threatening adverse effects of dipyrone","volume":"32","author":"Yigit","year":"2012","journal-title":"Turk Klinikleri J Med Sci."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1002\/jcph.1512","article-title":"Metamizole (dipyrone) and the liver: a review of the literature","volume":"59","author":"Lutz","year":"2019","journal-title":"J Clin Pharmacol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1111\/cea.13689","article-title":"Metamizole-induced reactions as a paradigm of drug hypersensitivity: non-allergic reactions, anaphylaxis, and delayed-type allergy","volume":"50","author":"Trautmann","year":"2020","journal-title":"Clin Exp Allergy."},{"key":"B53","first-page":"1","article-title":"Cutaneous reactions to drugs with special reference to severe bullous mucocutaneous eruptions and sulphonamides","volume":"68","author":"Kauppinen","year":"1972","journal-title":"Acta Derm Venereol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.therap.2019.01.009","article-title":"Bullous fixed drug eruption: a potential diagnostic pitfall: a study of 18 cases","volume":"74","author":"Zaouak","year":"2019","journal-title":"Therapie."},{"key":"B55","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/j.1600-0536.2011.01946.x","article-title":"Patch testing in fixed drug eruptions\u2013a 20-year review","volume":"65","author":"Andrade","year":"2011","journal-title":"Contact Dermatitis."},{"key":"B56","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/bjd.12125","article-title":"A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions","volume":"168","author":"Barbaud","year":"2013","journal-title":"Br J Dermatol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1125754\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T23:28:33Z","timestamp":1692055713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1125754\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,14]]},"references-count":56,"alternative-id":["10.3389\/fmed.2023.1125754"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1125754","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,14]]},"article-number":"1125754"}}